We describe a family with an R1668W mutation in the CACNA1A gene who presented with a broader clinical spectrum and more variable features than previously reported. The mother had a pure progressive cerebellar ataxia of late onset with downbeat nystagmus, whereas her daughter suffered from episodic ataxia, hemiplegic migraine, and progressive cerebellar ataxia with horizontal gaze-evoked and rebound nystagmus. In both patients, treatment with acetazolamide was ineffective and worsened baseline ataxia, whereas flunarizine ameliorated episodic symptoms. Our report highlights profound phenotypic variability that can be associated with CACNA1A mutations and adds important therapeutic considerations.

1.
Westenbroek RE, Sakurai T, Elliott EM, et al: Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J Neurosci 1995;15:6403–6418.
2.
Ophoff RA, Terwindt GM, Vergouwe MN, et al: Familial hemiplegic migraine and episodic ataxia type 2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543–552.
3.
Zhuchenko O, Bailey J, Bonnen P, et al: Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997;15:62–69.
4.
Jouvenceau A, Eunson LH, Spauschus A, et al: Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet 2001;358:801–807.
5.
Jen J, Wan J, Graves M, et al: Loss-of-function EA2 mutations are associated with impaired neuromuscular transmission. Neurology 2001;57:1843–1848.
6.
Ducros A, Denier C, Joutel A, et al: The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 2001;345:17–24.
7.
Jen J, Kim GW, Baloh RW: Clinical spectrum of episodic ataxia type 2. Neurology 2004;62:17–22.
8.
Geschwind DH, Perlman S, Figueroa KP, et al: Spinocerebellar ataxia type 6. Frequency of the mutation and genotype-phenotype correlations. Neurology 1997;49:1247–1251.
9.
Jodice C, Mantuano E, Veneziano L, et al: Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 1997;6:1973–1978.
10.
Yue Q, Jen JC, Nelson SF, et al: Progressive ataxia due to a missense mutation in a calcium-channel gene. Am J Hum Genet 1997;61:1078–1087.
11.
Marti S, Straumann D, Glasauer S: The origin of downbeat nystagmus: an asymmetry in the distribution of on-directions of vertical gaze-velocity Purkinje cells. Ann NY Acad Sci 2005;1039:548–553.
12.
Shams’ili S, Grefkens J, de Leeuw B, et al: Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409–1418.
13.
Boel M, Casaer P: Familial periodic ataxia responsive to flunarizine. Neuropediatrics 1988;19:218–220.
14.
Klockgether T, Schroth G, Diener HC, Dichgans J: Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990;53:297–305.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.